Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Merrimack Pharmaceuticals
With
Sanofi
This is a multicenter, open-label, randomized, Phase II study of MM-121 in patients with platinum resistant or refractory recurrent/advanced ovarian cancers. Up to 210 patients will be randomized (2:1) to receive MM-121 plus paclitaxel or paclitaxel alone.
Age
18–any
Sex
FEMALE
Healthy volunteers
Not accepted
You may be eligible if
Locally advanced/metastatic or recurrent epithelial ovarian cancer, fallopian tube cancer or primary peritoneal cancer
Received at least one prior platinum based chemotherapy regimen
Platinum-resistant or refractory
Eligible for weekly paclitaxel
Adequate liver and kidney function
18 years of age or above
You may not be if
Evidence of any other active malignancy
History of severe allergic reactions to paclitaxel or other drugs formulated in Cremophor®EL
